Dr. Bruce Montgomery, a UW Medicine oncologist, hopes that patients won't see these numbers and just throw up their hands in fear or resignation.

There is a general consensus among clinicians that a serum prostate-specific antigen (PSA) level ≥4.0 ng/ml is predictive of prostate cancer, and necessitates a biopsy. But there is a dearth of ...

Because of the large impact of prostate cancer, there is great interest in new methods of prevention and treatment; some of these appear to reduce mortality. [4] Lycopene is a natural product that ...

Prostate cancer is one of the most frequently diagnosed cancers in men. Prostate tumor staging and disease aggressiveness are evaluated based on the Gleason scoring system, which is further used to ...

In 2020, cancer incidence decreased from prepandemic levels for all demographic groups; there was no strong association observed for the magnitude of decline with the study's proxies for health ...

Incidence rates increased for prostate ... New cancer diagnoses were 8% lower than expected in 2020 due to the COVID-19, though rates returned to expected levels in 2021. Rates of late-stage ...

The annual cancer statistics report from the National Cancer ... the most common cancer types between 2018 and 2022, including prostate, liver and intrahepatic bile duct, esophagus, melanoma ...

when cancer incidence rates fell significantly, the report shows, possibly because of disruptions in medical care related to the COVID-19 pandemic. After 2020, they returned to expected levels.

"Our results suggest that this increase in arsenic levels could significantly elevate the incidence of heart disease, diabetes, and other non-cancer health effects," said author Lewis Ziska ...

Bayer has won a key FDA approval to extend the use of its prostate cancer therapy Nubeqa, as it tries to claim market share from rival drugs and fulfil its aim of building the drug into a €3 ...